PROCEPT BioRobotics Makes Key Progress in Prostate Cancer Clinical Trials
PROCEPT BioRobotics (NASDAQ:PRCT) has achieved two major milestones with its WATER IV prostate cancer clinical program. The company received FDA approval for a second randomized study and completed patient enrollment in the first trial comparing Aquablation therapy to radical prostatectomy. Leerink recently downgraded the stock from Outperform to Market Perform, but still sees over 33% upside potential.
Tickers: $PRCT
Topics: clinical trials FDA approval prostate cancer treatment robotics